Antipsychotic Medication-Induced Dysphoria: Its Meaning, Association with Typical vs. Atypical Medications and Impact on Adherence

Psychiatric Quarterly

Volumn 86, Issue 2, 2015, Pages 199-205

  Wu, Hanjing Emily ^a,b   Okusaga, Olaoluwa O ^a,b  

^a University of Texas Harris County Psychiatric Center   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Adherence; Dysphoria; First generation antipsychotics; Neuroleptics; Schizophrenia; Second generation antipsychotics

Indexed keywords

DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

AKATHISIA; ANGER; ANTIPSYCHOTIC INDUCED DYSPHORIA; ANXIETY; ARTICLE; DEPRESSION; DISEASE SEVERITY; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; GUILT; HOSTILITY; HUMAN; META ANALYSIS; PATHOGENESIS; PATIENT COMPLIANCE; PREVALENCE; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TENSION; CHEMICALLY INDUCED; EMOTIONAL DISORDER; MEDICATION COMPLIANCE;

AFFECTIVE SYMPTOMS; ANTIPSYCHOTIC AGENTS; HUMANS; MEDICATION ADHERENCE;

EID: 84928256048     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-014-9319-1     Document Type: Article

References (39)

1. King C, Voruganti LN: What’s in a name? The evolution of the nomenclature of antipsychotic drugs. Journal of Psychiatry and Neuroscience 27:168–175, 2002.
2. Harrison PJ: The neuropathological effects of antipsychotic drugs. Schizophrenia Research 40:87–99, 1999.
3. Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51–68, 1999.
4. King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 167:480–482, 1995.
5. Lynch G, Green JF, King DJ: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 169:524, 1996.
6. Noordsy DL, Drake RE, Teague GB, Osher FC, Hurlbut SC, Beaudett MS, et al.: Subjective experiences related to alcohol use among schizophrenics. The Journal of nervous and mental disease 179:410–414, 1991.
7. Mueser KT, Drake RE, Wallach MA: Dual diagnosis: a review of etiological theories. Addictive Behaviors 23:717–734, 1998.
8. Voruganti LN, Heslegrave RJ, Awad AG: Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. The Journal of Nervous and Mental Disease 185:463–465, 1997.
9. Awad AG, Voruganti LN: Quality of life and new antipsychotics in schizophrenia. Are patients better off? International Journal of Social Psychiatry 45:268–275, 1999.
10. Singh MM, Smith JM: Kinetics and dynamics of response to haloperidol in acute schizophrenia–A longitudinal study of the therapeutic process. Comprehensive Psychiatry 14:393–414, 1973.
11. Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American journal of psychiatry 136:1576, 1979.
12. Bruun RD: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. The American Journal of Psychiatry 145:621–624, 1988.
13. Weiden PJ, John Mann J, Dixon L, Haas G, Dechillo N, Frances AJ: Is neuroleptic dysphoria a healthy response? Comprehensive Psychiatry 30:546–552, 1989.
14. Newcomer JW, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG: Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. The British Journal of Psychiatry 164:834–838, 1994.
15. Awad AG, Voruganti L: New antipsychotics, compliance, quality of life, and subjective tolerability–are patients better off? Canadian Journal of Psychiatry 49:297–302, 2004.
16. Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al: Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25:642–650, 2001.
17. Voruganti L, Awad AG: Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatrica Scandinavica 111:22–28, 2005.
18. Voruganti L, Awad AG: Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171:121–132, 2004.
19. Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American Journal of Psychiatry 136:1216–1217, 1979.
20. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43:135–145, 2000.
21. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al.: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Research 57:201–208, 2002.
22. Cook PE, Goldberg JO, and Van Lieshout RJ: Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Canadian Journal of Psychiatry 47:870–874, 2002.
23. Naber D, Karow A, Lambert M: Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica. Supplementum 111:29–34, 2005.
24. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al.: Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50:79–88, 2001.
25. Harvey PD, Rabinowitz J, Eerdeken S, Davidson M: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. The American Journal of Psychiatry 162:1888–1895, 2005.
26. Marder SR: Lessons from each drug trial. The American Journal of Psychiatry 164:375–376, 2007.
27. Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatrica Scandinavica 111:81–83, 2005.
28. Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Larsen TK et al.: Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early Intervention in Psychiatry 3:58–65, 2009.
29. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C et al.: Maintenance treatment of schizophrenia with risperidone or haloperidol: 2 year outcomes. American Journal of Psychiatry 160:1405–1412, 2003.
30. Awad A, Hogan T: Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica 89:27–32, 1994.
31. Van Putten T, May PR, Marder SR, Wittmann LA: Subjective response to antipsychotic drugs. Archives of General Psychiatry 38:187–190, 1981.
32. Van Putten T, May R: Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Archives of General Psychiatry 35:477–480, 1978.
33. Hogan T, Awad A: Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychological Medicine 22:347–352, 1992.
34. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J: Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8, 2006.
35. Koob GF, Le Moal M: Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58, 1997.
36. Fibiger HC: Neurobiology of depression: focus on dopamine. Advances in Biochemical Psychopharmacology 49:1–17, 1995.
37. Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience 18:463–495, 1995.
38. Wise RA: Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319–340, 1996.
39. Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al.: Subjective effects of AMPT induced dopamine depletion in schizophrenia; the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology 25:642–650, 2001.